Home Stock

Stock Research: EyePoint

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

EyePoint

NMQ:EYPT US30233G1004
16
  • Value
    51
  • Growth
    14
  • Safety
    Safety
    19
  • Combined
    16
  • Sentiment
    55
  • 360° View
    360° View
    16
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. They operate in the biopharmaceutical industry. The company's operations are global. In the last fiscal year, the company had a market cap of $687 million, profits of $40 million, revenue of $43 million, and 165 employees.

more

ANALYSIS: With an Obermatt 360° View of 11 (better than 11% compared with alternatives), overall professional sentiment and financial characteristics for the stock EyePoint are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for EyePoint. The consolidated Sentiment Rank has a good rank of 55, which means that professional investors are more optimistic about the stock than for 55% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 48, which means that the share price of EyePoint is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 10, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 10% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 19 which means that the company has a riskier financing structure than 81% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Price vs. Book (P/B)
Country USA
Industry Pharmaceuticals
Size Small
Website eyepoint.bio
Index
NASDAQ
EyePoint stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
51 29 6 35
Growth
14 5 75 45
Safety
Safety
19 76 32 33
Sentiment
55 39 100 65
360° View
360° View
16 18 64 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 91 69 63
Opinions Change
18 56 88 50
Pro Holdings
n/a 8 84 76
Market Pulse
60 26 42 22
Sentiment
55 39 100 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
51 29 6 35
Growth
14 5 75 45
Safety Safety
19 76 32 33
Combined
16 21 18 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
1 7 7 28
Price vs. Earnings (P/E)
59 26 26 26
Price vs. Book (P/B)
100 64 9 46
Dividend Yield
1 1 1 1
Value
51 29 6 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 1 61 75
Profit Growth
10 6 64 37
Capital Growth
41 84 17 19
Stock Returns
82 7 100 61
Growth
14 5 75 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
61 100 52 18
Refinancing
46 69 37 65
Liquidity
1 10 17 33
Safety Safety
19 76 32 33

Similar Stocks

Discover high‑ranked alternatives to EyePoint and broaden your portfolio horizons.

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Regeneron Pharmaceuticals

NSQ:REGN
Country: USA
Industry: Biotechnology
Size: Large
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews